IRIS Accounts Production v24.3.2.46 08408459 director 27.4.23 26.4.24 26.4.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh084084592023-04-26084084592024-04-26084084592023-04-272024-04-26084084592022-04-30084084592022-05-012023-04-26084084592023-04-2608408459ns15:EnglandWales2023-04-272024-04-2608408459ns14:PoundSterling2023-04-272024-04-2608408459ns10:Director12023-04-272024-04-2608408459ns10:PrivateLimitedCompanyLtd2023-04-272024-04-2608408459ns10:SmallEntities2023-04-272024-04-2608408459ns10:AuditExempt-NoAccountantsReport2023-04-272024-04-2608408459ns10:SmallCompaniesRegimeForDirectorsReport2023-04-272024-04-2608408459ns10:SmallCompaniesRegimeForAccounts2023-04-272024-04-2608408459ns10:FullAccounts2023-04-272024-04-260840845912023-04-272024-04-2608408459ns5:CurrentFinancialInstruments2024-04-2608408459ns5:CurrentFinancialInstruments2023-04-2608408459ns5:Non-currentFinancialInstruments2024-04-2608408459ns5:Non-currentFinancialInstruments2023-04-2608408459ns5:ShareCapital2024-04-2608408459ns5:ShareCapital2023-04-2608408459ns5:RetainedEarningsAccumulatedLosses2024-04-2608408459ns5:RetainedEarningsAccumulatedLosses2023-04-2608408459ns10:RegisteredOffice2023-04-272024-04-2608408459ns5:IntangibleAssetsOtherThanGoodwill2023-04-272024-04-2608408459ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-04-272024-04-2608408459ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-04-2608408459ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-04-2608408459ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-04-2608408459ns5:LandBuildingsns5:ShortLeaseholdAssets2023-04-2608408459ns5:PlantMachinery2023-04-2608408459ns5:LandBuildingsns5:ShortLeaseholdAssets2023-04-272024-04-2608408459ns5:PlantMachinery2023-04-272024-04-2608408459ns5:LandBuildingsns5:ShortLeaseholdAssets2024-04-2608408459ns5:PlantMachinery2024-04-2608408459ns5:LandBuildingsns5:ShortLeaseholdAssets2023-04-2608408459ns5:PlantMachinery2023-04-2608408459ns5:WithinOneYearns5:CurrentFinancialInstruments2024-04-2608408459ns5:WithinOneYearns5:CurrentFinancialInstruments2023-04-260840845912023-04-272024-04-26
REGISTERED NUMBER: 08408459 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 26 APRIL 2024

FOR

ICE HEALTH CRYOTHERAPY LIMITED

ICE HEALTH CRYOTHERAPY LIMITED (REGISTERED NUMBER: 08408459)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 26 APRIL 2024










Page

Statement of Financial Position 1 to 2

Notes to the Financial Statements 3 to 6


ICE HEALTH CRYOTHERAPY LIMITED (REGISTERED NUMBER: 08408459)

STATEMENT OF FINANCIAL POSITION
26 APRIL 2024

26.4.24 26.4.23
Notes £    £   
FIXED ASSETS
Intangible assets 4 31,987 33,982
Tangible assets 5 48,586 51,467
80,573 85,449

CURRENT ASSETS
Stocks 84,960 65,000
Debtors 6 - 3,683
84,960 68,683
CREDITORS
Amounts falling due within one year 7 (21,453 ) (40,686 )
NET CURRENT ASSETS 63,507 27,997
TOTAL ASSETS LESS CURRENT
LIABILITIES

144,080

113,446

CREDITORS
Amounts falling due after more than one
year

8

(137,758

)

(107,572

)
NET ASSETS 6,322 5,874

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 6,222 5,774
6,322 5,874

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 26 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 26 April 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

ICE HEALTH CRYOTHERAPY LIMITED (REGISTERED NUMBER: 08408459)

STATEMENT OF FINANCIAL POSITION - continued
26 APRIL 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 25 April 2025 and were signed by:





A Paszynska - Director


ICE HEALTH CRYOTHERAPY LIMITED (REGISTERED NUMBER: 08408459)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 26 APRIL 2024


1. STATUTORY INFORMATION

ICE HEALTH CRYOTHERAPY LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 08408459

Registered office: C/o D P C
Stone House
55 Stone Road Business Park
Stoke on Trent
Staffordshire
ST4 6SR

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
The preparation of the financial statements requires management to make judgements, estimates
and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

(i) Useful economic lives of tangible assets

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful
economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and physical condition of the assets. See tangible assets note for the carrying amount of the assets and the accounting policy for the useful economic lives for each class of assets.

Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of twenty five years.

ICE HEALTH CRYOTHERAPY LIMITED (REGISTERED NUMBER: 08408459)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 26 APRIL 2024


2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Leasehold property - 25 years straight line
Plant and machinery - 15% reducing balance

Impairment of Fixed Assets

A review for indicators of impairment is carried out at each reporting date, with recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

For the purpose of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash- generating unit to which the asset belongs. The cash- generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or group of assets.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.


ICE HEALTH CRYOTHERAPY LIMITED (REGISTERED NUMBER: 08408459)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 26 APRIL 2024


2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. INTANGIBLE FIXED ASSETS
Development
costs
£   
COST
At 27 April 2023
and 26 April 2024 49,865
AMORTISATION
At 27 April 2023 15,883
Amortisation for year 1,995
At 26 April 2024 17,878
NET BOOK VALUE
At 26 April 2024 31,987
At 26 April 2023 33,982

ICE HEALTH CRYOTHERAPY LIMITED (REGISTERED NUMBER: 08408459)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 26 APRIL 2024


5. TANGIBLE FIXED ASSETS
Short Plant and
leasehold machinery Totals
£    £    £   
COST
At 27 April 2023
and 26 April 2024 72,035 26,070 98,105
DEPRECIATION
At 27 April 2023 28,812 17,826 46,638
Charge for year 2,881 - 2,881
At 26 April 2024 31,693 17,826 49,519
NET BOOK VALUE
At 26 April 2024 40,342 8,244 48,586
At 26 April 2023 43,223 8,244 51,467

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
26.4.24 26.4.23
£    £   
Other debtors - 3,683

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
26.4.24 26.4.23
£    £   
Bank loans and overdrafts 9,646 6,820
Trade creditors 663 -
Taxation and social security 8,566 31,451
Other creditors 2,578 2,415
21,453 40,686

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
26.4.24 26.4.23
£    £   
Amounts owed to group undertakings 93,971 85,265
Other creditors 43,787 22,307
137,758 107,572

9. RELATED PARTY DISCLOSURES

All transactions with related parties were conducted under normal market conditions and/or not material.

10. POST BALANCE SHEET EVENTS

There were no material events up to the date of approval of the financial statements by the board.